trimetrexate has been researched along with Mesothelioma in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vogelzang, NJ | 1 |
| Weissman, LB | 1 |
| Herndon, JE | 1 |
| Antman, KH | 1 |
| Cooper, MR | 1 |
| Corson, JM | 1 |
| Green, MR | 1 |
1 trial available for trimetrexate and Mesothelioma
| Article | Year |
|---|---|
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
Topics: Adult; Aged; Female; Humans; Male; Mesothelioma; Middle Aged; Survival Analysis; Treatment Outcome; | 1994 |